Management of Adult Primary Immune Thrombocytopenia: DelphiBased Consensus Recommendations

Basit Öğe Kaydı
dc.authoridAyer, Mesut/0000-0003-1977-0104
dc.authorwosidAyer, Mesut/U-5707-2018
dc.contributor.authorDemir, Ahmet Muzaffer
dc.contributor.authorUmit, Elif Gulsum
dc.contributor.authorAr, Muhlis Cem
dc.contributor.authorAyer, Mesut
dc.contributor.authorAyli, Meltem
dc.contributor.authorKarakus, Volkan
dc.contributor.authorKaya, Emin
dc.date.accessioned2024-08-04T20:56:05Z
dc.date.available2024-08-04T20:56:05Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: Primary immune thrombocytopenia (pITP) is an acquired autoimmune disorder related to the increased destruction and/or impaired production of platelets. Its diagnosis and management are challenging and require expertise and the interpretation of international consensus reports and guidelines with national variations in availability. We aimed to assess the agreement of hematologists in T & uuml;rkiye on certain aspects of both first -line and second -line management of patients with pITP. Materials and Methods: Applying a modified Delphi method, the Turkish National ITP Working Group (14 steering committee members), founded under the auspices of the Turkish Society of Hematology, developed a 21 -item questionnaire consisting of statements regarding the first -line and second -line treatment of pITP. A total of 107 adult hematologists working in either university or state hospitals voted for their agreement or disagreement with the statements in two consecutive rounds. Results: The participants reached consensus on the use of corticosteroids as first -line treatment and with limited duration. Methylprednisolone was the corticosteroid of choice rather than dexamethasone. Use of intravenous immunoglobulin was not preferred for patients without bleeding. It was also agreed that thrombopoietin receptor antagonists (TPO-RAs) or rituximab should be recommended as second -line treatment and that splenectomy could be considered 12-24 months after diagnosis in patients with chronic pITP. Conclusion: The optimization of the dose and duration of TPO-RAs in addition to corticosteroids is necessary to improve the management of patients with pITP.en_US
dc.description.sponsorshipAbdi Idot;brahim Pharmaceuticalsen_US
dc.description.sponsorshipThis study was financially supported by Abdi & Idot;brahim Pharmaceuticals.en_US
dc.identifier.doi10.4274/tjh.galenos.2024.2024.0055
dc.identifier.endpage104en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue2en_US
dc.identifier.pmid38545671en_US
dc.identifier.scopus2-s2.0-85195228745en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage97en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2024.2024.0055
dc.identifier.urihttps://hdl.handle.net/11616/102038
dc.identifier.volume41en_US
dc.identifier.wosWOS:001245706200003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdult primary immune thrombocytopeniaen_US
dc.subjectManagementen_US
dc.subjectDelphi methoden_US
dc.titleManagement of Adult Primary Immune Thrombocytopenia: DelphiBased Consensus Recommendationsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu